Jun 23, 2020 / 06:00PM GMT
Guyn Kim - BMO Capital Markets Equity Research - Analyst
Good afternoon. My name is Do Kim. I'm one of the biotech analysts at BMO. For our next fireside chat, we have with us Eric Swayze, SVP of Research at Ionis Pharmaceuticals; and Wade Walke, Head of Investor Relations.
Questions and Answers:
Guyn Kim - BMO Capital Markets Equity Research - AnalystCould you start by providing us a brief update of the commercial products and the typical goals for this year for the late case trials and the proof-of-concept studies you're running?
D. Wade Walke - Ionis Pharmaceuticals, Inc. - VP of IR
You bet. I'll kick it off. This is a Wade Walke. It's a very exciting time for us at Ionis. We have a lot of things going on, as we usually do. We have -- but this year's -- it's kind of a special year. We have a new CEO, Brett Monia, who has a vision to build off the tremendous achievements of the last 30 years and take the company really to the next level, with the vision of Ionis as really the leader in biotech and a company
Trustpilot
